- Home
- TNGX vs CADL Comparison
TNGX vs CADL Comparison
Compare TNGX & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | CADL |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNGX | CADL |
|---|---|---|
| Price | $9.05 | $5.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $12.50 | ★ $19.43 |
| AVG Volume (30 Days) | ★ 2.7M | 960.7K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,501,000.00 | N/A |
| Revenue This Year | $53.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.29 | N/A |
| 52 Week Low | $1.03 | $4.25 |
| 52 Week High | $11.20 | $13.68 |
Technical Indicators
Market Signals| Indicator | TNGX | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 57.77 |
| Support Level | $8.89 | $5.39 |
| Resistance Level | $10.08 | $6.83 |
| Average True Range (ATR) | 0.61 | 0.41 |
| MACD | -0.16 | 0.14 |
| Stochastic Oscillator | 8.07 | 55.62 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.